Stock AMRN AMARIN CORPORATION PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Amarin Corporation plc

Equities

AMRN

US0231112063

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
0.8475 USD +0.38% Intraday chart for Amarin Corporation plc -2.59% -2.59%
May. 13 European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher MT
May. 10 European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3% MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 7,695 1,901 1,333 488.6 355.2 348.2 - -
Enterprise Value (EV) 1 7,101 1,400 1,114 270.4 156 304.3 189.6 317.2
P/E ratio -306 x -97.8 x 169 x -4.65 x -5.8 x -4.81 x -5.1 x -21.2 x
Yield - - - - - - - -
Capitalization / Revenue 17.9 x 3.1 x 2.29 x 1.32 x 1.16 x 1.72 x 1.62 x 1.29 x
EV / Revenue 16.5 x 2.28 x 1.91 x 0.73 x 0.51 x 1.51 x 0.88 x 1.17 x
EV / EBITDA -295 x -73.5 x 44.9 x -5.69 x -2.31 x -6.02 x -3.46 x 14 x
EV / FCF -600 x -63.7 x -16.7 x -1.5 x 22.7 x 14.5 x - -
FCF Yield -0.17% -1.57% -5.97% -66.8% 4.41% 6.9% - -
Price to Book 12.1 x 2.97 x 2 x 0.82 x 0.64 x 0.7 x 0.76 x -
Nbr of stocks (in thousands) 358,907 388,829 395,629 403,829 408,292 410,869 - -
Reference price 2 21.44 4.890 3.370 1.210 0.8700 0.8475 0.8475 0.8475
Announcement Date 2/25/20 2/25/21 3/1/22 3/1/23 2/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 429.8 614.1 583.2 369.2 306.9 202.1 214.9 270.6
EBITDA 1 -24.1 -19.06 24.81 -47.5 -67.43 -50.54 -54.8 22.62
EBIT 1 -24.28 -19.66 24.22 -74.26 -67.59 -56.6 -42.17 13.06
Operating Margin -5.65% -3.2% 4.15% -20.12% -22.02% -28% -19.63% 4.82%
Earnings before Tax (EBT) 1 -22.48 -17.26 11.29 -103.8 -53.67 -51.77 -48.45 14.48
Net income 1 -22.64 -18 7.729 -105.8 -59.11 -70.47 -64.91 -15.78
Net margin -5.27% -2.93% 1.33% -28.66% -19.26% -34.87% -30.21% -5.83%
EPS 2 -0.0700 -0.0500 0.0200 -0.2600 -0.1500 -0.1763 -0.1663 -0.0400
Free Cash Flow 1 -11.84 -22 -66.53 -180.7 6.88 21 - -
FCF margin -2.76% -3.58% -11.41% -48.94% 2.24% 10.39% - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 2/25/20 2/25/21 3/1/22 3/1/23 2/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 144.5 94.63 94.44 89.88 90.24 85.98 80.17 66.06 74.71 56.52 48.62 46.7 50.29 48.24
EBITDA 15.88 -27.53 -37.48 -5.006 -3.029 -17.28 - - -4.804 - - - - -
EBIT 1 15.74 -28.31 -37.62 1.427 -9.766 -17.34 -23.96 -21.45 -4.837 -13.58 -13.26 -15.02 -14.72 -4.997
Operating Margin 10.89% -29.91% -39.83% 1.59% -10.82% -20.17% -29.89% -32.47% -6.47% -24.03% -27.27% -32.17% -29.27% -10.36%
Earnings before Tax (EBT) 1 16.39 -28.35 -64.8 -3.883 -6.773 -14.5 -17.92 -18.81 -2.449 -8.655 -15.6 -15.2 -15.4 -
Net income 1 14.7 -31.56 -69.96 -5.14 0.856 -16.46 -17.56 -19.31 -5.781 -9.953 -23.1 -24.1 -21.05 -
Net margin 10.17% -33.35% -74.07% -5.72% 0.95% -19.15% -21.9% -29.23% -7.74% -17.61% -47.51% -51.61% -41.86% -
EPS 2 0.0400 -0.0800 -0.1800 -0.0100 - -0.0400 -0.0400 -0.0500 -0.0100 -0.0200 -0.0475 -0.0525 -0.0500 -0.0100
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 3/1/22 5/4/22 8/3/22 10/27/22 3/1/23 5/3/23 8/2/23 11/1/23 2/29/24 5/1/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 594 501 219 218 199 43.9 159 31
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -11.8 -22 -66.5 -181 6.88 21 - -
ROE (net income / shareholders' equity) -5.95% -2.91% 1.19% -16.8% -5.15% -14.5% -13.3% -
ROA (Net income/ Total Assets) -3.57% -1.95% 0.76% -10.8% -3.44% -9.52% -8.33% -
Assets 1 634 924.1 1,017 977.1 1,718 740.3 779 -
Book Value Per Share 2 1.780 1.640 1.680 1.480 1.350 1.210 1.120 -
Cash Flow per Share - - - - - - - -
Capex 1 2.48 0.25 - 0.6 - 0.5 0.5 0.5
Capex / Sales 0.58% 0.04% - 0.16% - 0.25% 0.23% 0.18%
Announcement Date 2/25/20 2/25/21 3/1/22 3/1/23 2/29/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Amarin Corporation plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
0.8475 USD
Average target price
1 USD
Spread / Average Target
+17.99%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
AMARIN CORPORATION PLC Stock Amarin Corporation plc
-2.59% 348M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+12.30% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.15% 106B
BIONTECH SE Stock BioNTech SE
-8.14% 23.4B
ARGENX SE Stock argenx SE
-1.31% 21.78B
GENMAB A/S Stock Genmab A/S
-9.05% 18.09B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.25% 16.72B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.33% 15.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.80% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.03% 11.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. AMRN Stock
  4. Financials Amarin Corporation plc